Linkedin
RLS logo_header
Linkedin

Stipple Bio Launches with $100M Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline

“We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics,” said Jeff Landau, Chief Executive Officer of Stipple Bio. “This funding positions us to progress STP-100 into the clinic and continue building a broad oncology pipeline. I am extremely pleased to have the support of industry-leading investors who share our enthusiasm towards developing precision and differentiated cancer therapies based on our modality-agnostic Pointillist Platform.”

Read the full story on "Stipple Bio Launches with $100M Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline"

Share:

More News

TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors

“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer

“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in

Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers

“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of

First Patient Dosed in Ph 1/2 Study of MT-304 in HER2-Positive Solid Tumors

Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo